| Lived experience submissions on new treatments and medicines, part of national working group looking at HTA reform, part of industry campaign to improve timeliness of HTA approval [Australia]. | 呼吸系統
> 肺部疾病 | 監管合作關係
> 參與健康技術評估（HTA）及給付審查 | Over 100,000 | National | Regularly | 119011106646 |
| Work with PBAC [Pharmaceutical Benefits Advisory Committee], HTA [Health Technology Assessment], TGA [Therapeutic Goods Administration], and MSAC [Medical Services Advisory Committee], as well as patient groups and Medicines Australia Australia to advocate for access and equity for treatments and care. | 神經肌肉
> 肌肉萎縮症 | 監管合作關係
> 參與健康技術評估（HTA）及給付審查 | 1,000 | National | Regularly | 119021570524 |
| We support and advocate for enhancement of the involvement of patients/carers in Health Technology. We have been involved in the Co design group Enhancing Consumer involvement in Australian Health technology assessment and in the HTA Review process. | 巨蟹座
> 癌症：大多數類型 | 監管合作關係
> 參與健康技術評估（HTA）及給付審查 | We do not communicate with patients directly | Regional | Sometimes | 119031444677 |
| Consumer feedback to PBAC [Pharmaceutical Benefits Advisory Committee], MSAC [Medical Services Advisory Committee], government consultations, and other organisations on behalf of those with kidney disease. | 腎臟
> 腎臟疾病 | 監管合作關係
> 參與健康技術評估（HTA）及給付審查 | Do not know | National | Regularly | 119051003447 |
| We provide public comment to the Pharmaceutical Benefits Advisory Committee [PBAC] for the reimbursement of medicines relating to asthma, including some vaccines. | 呼吸系統
> 氣喘 | 監管合作關係
> 參與健康技術評估（HTA）及給付審查 | Over 100,000 | National | Regularly | 119051065145 |
| PBAC [Pharmaceutical Benefits Advisory Committee] comments. | 皮膚
> 異位性皮膚炎／濕疹 | 監管合作關係
> 參與健康技術評估（HTA）及給付審查 | Over 100,000 | National | Regularly | 119051082840 |
| HTA [Health Technology Assessment] — lived experience. | 呼吸系統
> 肺部疾病 | 監管合作關係
> 參與健康技術評估（HTA）及給付審查 | Over 100,000 | National | Regularly | 119051865995 |
| We provide expertise to regulatory and funding decision-makers on topics like newborn screening, medicine listing, and model of care funding. | 稀有
> 罕見疾病：遺傳性 | 監管合作關係
> 參與健康技術評估（HTA）及給付審查 | 1,000 | National | Sometimes | 119054286714 |
| Involved in government [Australia] policy reviews - HTA review and Chronic Disease - submit responses to TGA [Therapeutic Goods Administration], MSAC [Medical Services Advisory Committee], and PBAC [Pharmaceutical Benefits Advisory Committee] in relation to sponsor requests. | 腸胃道
> IBD | 監管合作關係
> 參與健康技術評估（HTA）及給付審查 | Over 100,000 | National | Regularly | 119058351283 |
| PBAC [Pharmaceutical Benefits Advisory Committee], MSAC [Medical Services Advisory Committee], PL [Prostheses List]. | 心血管
> 心血管與心臟疾病 | 監管合作關係
> 參與健康技術評估（HTA）及給付審查 | Do not know | International | Regularly | 119061299937 |
| Our organisation exists to represent the interests of both community-led mental health service organisations and also the lived experience consumer community. A recent example of our work representing patient interests to regulators that are responsible for deciding drug pricing was recent correspondence we issued to the Australian Pharmaceutical Benefits Advisory Committee, requesting that a drug for the treatment of schizophrenia be listed on the Pharmaceutical Benefits Scheme. In this correspondence, we directly represented the views of patients and family and carers. | 心理健康
> 心理健康：大多數狀況 | 監管合作關係
> 參與健康技術評估（HTA）及給付審查 | 10,000 | National | Sometimes | 119074282308 |
| We provide public comment to the Pharmaceutical Benefits Advisory Committee for the reimbursement of medicines relating to asthma, including some vaccines. We write and support submissions to the Therapeutic Goods Administration for changes to medicines. Asthma Australia will lobby government if a change that is made is not in the best interest of people with asthma. | 呼吸系統
> 氣喘 | 監管合作關係
> 貢獻至行銷授權申請 | Over 100,000 | National | Regularly | 119051065145 |
| Work with PBAC [Pharmaceutical Benefits Advisory Committee], HTA [Health Technology Assessment], TGA [Therapeutic Goods Administration], and MSAC [Medical Services Advisory Committee], as well as patient groups and Medicines Australia Australia to advocate for access and equity for treatments and care. | 神經肌肉
> 肌肉萎縮症 | 監管合作關係
> 出席/主持與政策制定者/監管機構的會議 | 1,000 | National | Regularly | 119021570524 |
| Our organisation exists to represent the interests of both community-led mental health service organisations and also the lived experience consumer community. | 心理健康
> 心理健康：大多數狀況 | 監管合作關係
> 與其他醫療倡導者 | 10,000 | National | Sometimes | 119074282308 |
| Regular advocacy and lobbying to all levels of government on new and current diabetes medications and technology. | 內分泌
> 糖尿病（1型和2型） | 影響政策與立法
> 影響醫療保健政策與法規 | Over 100,000 | National | Regularly | 119023443093 |
| We provide public comment to the Pharmaceutical Benefits Advisory Committee for the reimbursement of medicines relating to asthma, including some vaccines. We write and support submissions to the Therapeutic Goods Administration for changes to medicines. Asthma Australia will lobby government if a change that is made is not in the best interest of people with asthma. | 呼吸系統
> 氣喘 | 影響政策與立法
> 影響醫療保健政策與法規 | Over 100,000 | National | Regularly | 119051065145 |
| Involved in government [Australia] policy reviews - HTA review and Chronic Disease - submit responses to TGA [Therapeutic Goods Administration], MSAC [Medical Services Advisory Committee], and PBAC [Pharmaceutical Benefits Advisory Committee] in relation to sponsor requests. | 腸胃道
> IBD | 影響政策與立法
> 影響醫療保健政策與法規 | Over 100,000 | National | Regularly | 119058351283 |
| Where possible, we add our advocacy voice to decision-makers. | 神經肌肉
> 肌肉萎縮症 | 影響政策與立法
> 影響醫療保健政策與法規 | 1,000 | National | Rarely | 119070072574 |
| Consumer feedback to PBAC [Pharmaceutical Benefits Advisory Committee], MSAC [Medical Services Advisory Committee], government consultations, and other organisations on behalf of those with kidney disease. | 腎臟
> 腎臟疾病 | 影響政策與立法
> 參與公開聽證會及諮詢 | Do not know | National | Regularly | 119051003447 |
| Public submissions. | 醫學研究
> 醫學研究 | 影響政策與立法
> 參與公開聽證會及諮詢 | 100 | National | Sometimes | 119075599019 |
| Pre-Budget Submissions, Advocacy activities, Meetings. | 風濕性
> 風濕性疾病：大多數類型 | 影響政策與立法
> 動員國會議員與政治領袖 | Over 100,000 | National | Regularly | 119017682842 |
| Weight loss drugs, general medicine costs. | 病患倡導
> 病患權利 | 定價與可負擔性倡議
> 倡導公平的藥品定價 | 100,000 | National | Sometimes | 119055318270 |
| Involved in government [Australia] policy reviews - HTA review and Chronic Disease - submit responses to TGA [Therapeutic Goods Administration], MSAC [Medical Services Advisory Committee], and PBAC [Pharmaceutical Benefits Advisory Committee] in relation to sponsor requests. | 腸胃道
> IBD | 定價與可負擔性倡議
> 倡導公平的藥品定價 | Over 100,000 | National | Regularly | 119058351283 |
| Pricing. | 風濕性
> 狼瘡 | 定價與可負擔性倡議
> 倡導公平的藥品定價 | 5,000 | International | Regularly | 119058972997 |
| Through an HTA [Health Technology Assessment] implementation review, direct advocacy around drug access and pricing, part of roundtables to more effectively advocate patient interests for change. | 神經系統
> 神經系統：其他 | 定價與可負擔性倡議
> 倡導公平的藥品定價 | We do not communicate with patients directly | National | Regularly | 119069368666 |
| We will sometimes complete Consumer Comments for the Pharmaceutical Benefits Advisory Committee if we feel that an immunization should be federally funded on the National Immunization Program. | 傳染性
> 免疫接種 | 定價與可負擔性倡議
> 倡導將產品納入給付清單/國家藥品目錄 | Over 100,000 | National | Sometimes | 119022383972 |
| Access to Palovarotene [to reduce the formation of abnomal bone tissue in people with It is indicated for patients with the ultra-rare genetic disorder Fibrodysplasia Ossificans Progressiva (FOP)] via the PBS [Pharmaceutical Benefits Scheme] listing. | 骨骼
> 進行性骨化性纖維發育不良（FOP） | 定價與可負擔性倡議
> 倡導將產品納入給付清單/國家藥品目錄 | 100 | National | Rarely | 119044789085 |
| Australia's PBS [Pharmaceutical Benefits Scheme] listings as an example. | 腎臟
> 腎臟疾病 | 定價與可負擔性倡議
> 倡導將產品納入給付清單/國家藥品目錄 | 5,000 | National | Regularly | 119050789619 |
| We provide expertise to regulatory and funding decision-makers on topics like newborn screening, medicine listing, and model of care funding. | 稀有
> 罕見疾病：遺傳性 | 定價與可負擔性倡議
> 倡導將產品納入給付清單/國家藥品目錄 | 1,000 | National | Sometimes | 119054286714 |
| Our organisation exists to represent the interests of both community-led mental health service organisations and also the lived experience consumer community. A recent example of our work representing patient interests to regulators that are responsible for deciding drug pricing was recent correspondence we issued to the Australian Pharmaceutical Benefits Advisory Committee, requesting that a drug for the treatment of schizophrenia be listed on the Pharmaceutical Benefits Scheme. In this correspondence, we directly represented the views of patients and family and carers. | 心理健康
> 心理健康：大多數狀況 | 定價與可負擔性倡議
> 倡導將產品納入給付清單/國家藥品目錄 | 10,000 | National | Sometimes | 119074282308 |
| Work with PBAC [Pharmaceutical Benefits Advisory Committee], HTA [Health Technology Assessment], TGA [Therapeutic Goods Administration], and MSAC [Medical Services Advisory Committee], as well as patient groups and Medicines Australia Australia to advocate for access and equity for treatments and care. | 神經肌肉
> 肌肉萎縮症 | 改善存取路徑
> 促進藥品/醫療保健的公平取得 | 1,000 | National | Regularly | 119021570524 |
| Weight loss drugs, general medicine costs. | 病患倡導
> 病患權利 | 改善存取路徑
> 促進藥品/醫療保健的公平取得 | 100,000 | National | Sometimes | 119055318270 |
| Regulations and restrictions regarding prescribing of antivirals for COVID to our patient cohort [neurological conditions]. | 神經系統
> 神經系統：其他 | 改善存取路徑
> 促進藥品/醫療保健的公平取得 | 5,000 | National | Rarely | 119056702514 |
| PBAC [Pharmaceutical Benefits Advisory Committee], MSAC [Medical Services Advisory Committee], PL [Prostheses List]. | 心血管
> 心血管與心臟疾病 | 改善存取路徑
> 促進藥品/醫療保健的公平取得 | Do not know | International | Regularly | 119061299937 |
| Through an HTA [Health Technology Assessment] implementation review, direct advocacy around drug access and pricing, part of roundtables to more effectively advocate patient interests for change. | 神經系統
> 神經系統：其他 | 改善存取路徑
> 促進藥品/醫療保健的公平取得 | We do not communicate with patients directly | National | Regularly | 119069368666 |
| Through an HTA [Health Technology Assessment] implementation review. | 神經系統
> 神經系統：其他 | 改善存取路徑
> 促進藥品/醫療保健的公平取得 | We do not communicate with patients directly | National | Regularly | 119069368666 |
| We will sometimes complete Consumer Comments for the Pharmaceutical Benefits Advisory Committee if we feel that an immunization should be federally funded on the National Immunization Program. | 傳染性
> 免疫接種 | 改善存取路徑
> 倡導更廣泛的疫苗取得管道 | Over 100,000 | National | Sometimes | 119022383972 |
| Access to Palovarotene [to reduce the formation of abnomal bone tissue in people with It is indicated for patients with the ultra-rare genetic disorder Fibrodysplasia Ossificans Progressiva (FOP)] via the PBS [Pharmaceutical Benefits Scheme] listing. | 骨骼
> 進行性骨化性纖維發育不良（FOP） | 改善存取路徑
> 改善罕見/極罕見療法的取得管道 | 100 | National | Rarely | 119044789085 |
| Consumer feedback to PBAC [Pharmaceutical Benefits Advisory Committee], MSAC [Medical Services Advisory Committee], government consultations, and other organisations on behalf of those with kidney disease. | 腎臟
> 腎臟疾病 | 以實證為基礎的病患意見
> 運用患者洞察來輔助決策 | Do not know | National | Regularly | 119051003447 |
| Lived experience submissions on new treatments and medicines, part of national working group looking at HTA reform, part of industry campaign to improve timeliness of HTA approval [Australia]. | 呼吸系統
> 肺部疾病 | 以實證為基礎的病患意見
> 運用病患故事與親身經歷敘述 | Over 100,000 | National | Regularly | 119011106646 |
| We support and advocate for enhancement of the involvement of patients/carers in Health Technology. We have been involved in the Co design group Enhancing Consumer involvement in Australian Health technology assessment and in the HTA Review process. | 巨蟹座
> 癌症：大多數類型 | 以實證為基礎的病患意見
> 運用病患故事與親身經歷敘述 | We do not communicate with patients directly | Regional | Sometimes | 119031444677 |
| HTA [Health Technology Assessment] — lived experience. | 呼吸系統
> 肺部疾病 | 以實證為基礎的病患意見
> 運用病患故事與親身經歷敘述 | Over 100,000 | National | Regularly | 119051865995 |
| Our organisation exists to represent the interests of both community-led mental health service organisations and also the lived experience consumer community. A recent example of our work representing patient interests to regulators that are responsible for deciding drug pricing was recent correspondence we issued to the Australian Pharmaceutical Benefits Advisory Committee, requesting that a drug for the treatment of schizophrenia be listed on the Pharmaceutical Benefits Scheme. In this correspondence, we directly represented the views of patients and family and carers. | 心理健康
> 心理健康：大多數狀況 | 以實證為基礎的病患意見
> 運用病患故事與親身經歷敘述 | 10,000 | National | Sometimes | 119074282308 |
| Pricing, clinical trials. | 風濕性
> 狼瘡 | 診斷與藥品配送
> 協作臨床試驗設計 | 5,000 | International | Regularly | 119058972997 |
| We provide expertise to regulatory and funding decision-makers on topics like newborn screening, medicine listing, and model of care funding. | 稀有
> 罕見疾病：遺傳性 | 診斷與藥品配送
> 支援篩檢與早期發現 | 1,000 | National | Sometimes | 119054286714 |
| We provide expertise to regulatory and funding decision-makers on topics like newborn screening, medicine listing, and model of care funding. | 稀有
> 罕見疾病：遺傳性 | 機構治理
> 確保在政府諮詢機構中獲得代表性 | 1,000 | National | Sometimes | 119054286714 |
| Preterm Infants Parents Association [PIPA] has representatives on numerous hospital and Queensland Health Department committees. | 兒童健康
> 新生兒 | 機構治理
> 確保在政府諮詢機構中獲得代表性 | 5,000 | Regional | Regularly | 119074312093 |
| Through an HTA [Health Technology Assessment] implementation review, direct advocacy around drug access and pricing, part of roundtables to more effectively advocate patient interests for change. | 神經系統
> 神經系統：其他 | 機構治理
> 在多方利害關係人網絡中有效運作 | We do not communicate with patients directly | National | Regularly | 119069368666 |
互動
行動與倡議
14 提及
